Free Trial Information
BioCentury | Sep 27, 2019
Finance

Via Munich office, Kurma launches oncology company Tacalyx

Tacalyx, the first company created from French VC Kurma’s new Munich office, signals continued interest in tumor-associated carbohydrate antigens (TACAs), the targeting of sugars up-regulated in cancers. Kurma Partners opened the German office early this...
Read More
BioCentury | May 18, 2018
Financial News

Acousia raises $12M in series B

Hearing loss company Acousia Therapeutics GmbH (Tübingen, Germany) raised €10 million ($12 million) on May 14 in a series B round led by LBBW Venture Capital. Fellow new investors Creathor Ventures and Bregua Corp. and...
Read More
BioCentury | May 14, 2018
Financial News

Acousia raises €10M in series B

Hearing loss company Acousia Therapeutics GmbH (Tübingen, Germany) raised €10 million ($12 million) in a series B round led by LBBW Venture Capital. Fellow new investors Creathor Ventures and Bregua Corp. and existing investors Boehringer...
Read More
BioCentury | Nov 11, 2016
Finance

Creathor’s therapeutic options

...pan-European VC to invest in therapeutics companies previously considered too capital-intensive. Karlheinz Schmelig told BioCentury Creathor Venture...
...life sciences fund, is targeting €120 million ($132.6 million), 50% more than the €80 million Creathor Venture...
...Pharmaceuticals AG , which has raised a total of $29.4 million over four venture rounds. Creathor Venture...
Read More
BioCentury | Jul 27, 2015
Financial News

Cevec completes venture financing

...Date completed: 2015-07-22 Type: Venture financing Raised: EUR4.5 million ($4.9 million) Investors: Investtodate; Peppermint VenturePartners; Creathor Venture...
Read More
BioCentury | Mar 31, 2014
Financial News

CAP-CMV completes venture financing

...Date completed: 3/24/14 Type: Venture financing Raised: €1.7 million ($2.3 million) Investors: Peppermint VenturePartners; NRW.Bank; Creathor Venture...
Read More
BioCentury | Aug 1, 2011
Financial News

Cevec completes venture financing

...Supply/Service, Biomanufacturing Date completed: 7/25/11 Type: Venture financing Raised: €6 million ($8.6 million) Investors: NRW.Bank; Creathor Venture...
Read More
BioCentury | Sep 27, 2010
Financial News

Phenex completes venture financing

...Germany Business: Metabolic, Endocrine, Cancer Date completed: 9/21/10 Type: Venture financing Raised: $7.9 million Investors: Creathor Venture...
Read More
BioCentury | May 24, 2010
Financial News

caprotec completes venture financing

...Business: Proteomics, Supply/Service Date completed: 5/13/10 Type: Venture financing Raised: €4 million ($4.9 million) Investors: Creathor Venture...
Read More
BioCentury | Nov 9, 2009
Financial News

Cevec completes venture financing

...Business: Supply/Service, Biomanufacturing Date completed: 11/3/09 Type: Venture financing Raised: €4 million ($5.9 million) Investors: Creathor Venture...
Read More
Items per page:
1 - 10 of 12
BioCentury | Sep 27, 2019
Finance

Via Munich office, Kurma launches oncology company Tacalyx

Tacalyx, the first company created from French VC Kurma’s new Munich office, signals continued interest in tumor-associated carbohydrate antigens (TACAs), the targeting of sugars up-regulated in cancers. Kurma Partners opened the German office early this...
Read More
BioCentury | May 18, 2018
Financial News

Acousia raises $12M in series B

Hearing loss company Acousia Therapeutics GmbH (Tübingen, Germany) raised €10 million ($12 million) on May 14 in a series B round led by LBBW Venture Capital. Fellow new investors Creathor Ventures and Bregua Corp. and...
Read More
BioCentury | May 14, 2018
Financial News

Acousia raises €10M in series B

Hearing loss company Acousia Therapeutics GmbH (Tübingen, Germany) raised €10 million ($12 million) in a series B round led by LBBW Venture Capital. Fellow new investors Creathor Ventures and Bregua Corp. and existing investors Boehringer...
Read More
BioCentury | Nov 11, 2016
Finance

Creathor’s therapeutic options

...pan-European VC to invest in therapeutics companies previously considered too capital-intensive. Karlheinz Schmelig told BioCentury Creathor Venture...
...life sciences fund, is targeting €120 million ($132.6 million), 50% more than the €80 million Creathor Venture...
...Pharmaceuticals AG , which has raised a total of $29.4 million over four venture rounds. Creathor Venture...
Read More
BioCentury | Jul 27, 2015
Financial News

Cevec completes venture financing

...Date completed: 2015-07-22 Type: Venture financing Raised: EUR4.5 million ($4.9 million) Investors: Investtodate; Peppermint VenturePartners; Creathor Venture...
Read More
BioCentury | Mar 31, 2014
Financial News

CAP-CMV completes venture financing

...Date completed: 3/24/14 Type: Venture financing Raised: €1.7 million ($2.3 million) Investors: Peppermint VenturePartners; NRW.Bank; Creathor Venture...
Read More
BioCentury | Aug 1, 2011
Financial News

Cevec completes venture financing

...Supply/Service, Biomanufacturing Date completed: 7/25/11 Type: Venture financing Raised: €6 million ($8.6 million) Investors: NRW.Bank; Creathor Venture...
Read More
BioCentury | Sep 27, 2010
Financial News

Phenex completes venture financing

...Germany Business: Metabolic, Endocrine, Cancer Date completed: 9/21/10 Type: Venture financing Raised: $7.9 million Investors: Creathor Venture...
Read More
BioCentury | May 24, 2010
Financial News

caprotec completes venture financing

...Business: Proteomics, Supply/Service Date completed: 5/13/10 Type: Venture financing Raised: €4 million ($4.9 million) Investors: Creathor Venture...
Read More
BioCentury | Nov 9, 2009
Financial News

Cevec completes venture financing

...Business: Supply/Service, Biomanufacturing Date completed: 11/3/09 Type: Venture financing Raised: €4 million ($5.9 million) Investors: Creathor Venture...
Read More
Items per page:
1 - 10 of 12